Literature DB >> 19018246

Targeted overexpression of human alpha-synuclein triggers microglial activation and an adaptive immune response in a mouse model of Parkinson disease.

Shaji Theodore1, Shuwen Cao, Pamela J McLean, David G Standaert.   

Abstract

Microglial activation and adaptive immunity have been implicated in the neurodegenerative processes in Parkinson disease. It has been proposed that these responses may be triggered by modified forms of alpha-synuclein (alpha-SYN), particularly nitrated species, which are released as a consequence of dopaminergic neurodegeneration. To examine the relationship between alpha-SYN, microglial activation, and adaptive immunity, we used a mouse model of Parkinson disease in which human alpha-SYN is overexpressed by a recombinant adeno-associated virus vector, serotype 2 (AAV2-SYN); this overexpression leads to slow degeneration of dopaminergic neurons. Microglial activation and components of the adaptive immune response were assessed using immunohistochemistry; quantitative polymerase chain reaction was used to examine cytokine expression. Four weeks after injection, there was a marked increase in CD68-positive microglia and greater infiltration of B and T lymphocytes in the substantia nigra pars compacta of the AAV2-SYN group than in controls. At 12 weeks, CD68 staining declined, but B- and T-cell infiltration persisted. Expression of proinflammatory cytokines was enhanced, whereas markers of alternative activation (i.e. arginase I and interleukins 4 and 13) were not altered. Increased immunoreactivity for mouse immunoglobulin was detected at all time points in the AAV2-SYN animals. These data show that overexpression of alpha-SYN alone, in the absence of overt neurodegeneration, is sufficient to trigger neuroinflammation with both microglial activation and stimulation of adaptive immunity.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19018246      PMCID: PMC2753200          DOI: 10.1097/NEN.0b013e31818e5e99

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  62 in total

1.  Alterations of T-lymphocyte populations in Parkinson disease.

Authors:  Yasuhiko Baba; Ataru Kuroiwa; Ryan J Uitti; Zbigniew K Wszolek; Tatsuo Yamada
Journal:  Parkinsonism Relat Disord       Date:  2005-09-09       Impact factor: 4.891

2.  Neuroprotective activities of CD4+CD25+ regulatory T cells in an animal model of Parkinson's disease.

Authors:  Ashley D Reynolds; Rebecca Banerjee; Jianou Liu; Howard E Gendelman; R Lee Mosley
Journal:  J Leukoc Biol       Date:  2007-08-03       Impact factor: 4.962

3.  Temporal mRNA profiles of inflammatory mediators in the murine 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrimidine model of Parkinson's disease.

Authors:  R Pattarini; R J Smeyne; J I Morgan
Journal:  Neuroscience       Date:  2007-01-29       Impact factor: 3.590

4.  Nitrated alpha-synuclein-activated microglial profiling for Parkinson's disease.

Authors:  Ashley D Reynolds; Jason G Glanzer; Irena Kadiu; Mary Ricardo-Dukelow; Anathbandhu Chaudhuri; Pawel Ciborowski; Ronald Cerny; Benjamin Gelman; Mark P Thomas; R Lee Mosley; Howard E Gendelman
Journal:  J Neurochem       Date:  2007-11-22       Impact factor: 5.372

5.  Characterization of intrastriatal recombinant adeno-associated virus-mediated gene transfer of human tyrosine hydroxylase and human GTP-cyclohydrolase I in a rat model of Parkinson's disease.

Authors:  R J Mandel; K G Rendahl; S K Spratt; R O Snyder; L K Cohen; S E Leff
Journal:  J Neurosci       Date:  1998-06-01       Impact factor: 6.167

6.  MHC class II positive microglia and lymphocytic infiltration are present in the substantia nigra and striatum in mouse model of Parkinson's disease.

Authors:  I Kurkowska-Jastrzebska; A Wrońska; M Kohutnicka; A Członkowski; A Członkowska
Journal:  Acta Neurobiol Exp (Wars)       Date:  1999       Impact factor: 1.579

7.  Effects of cerebrospinal fluid from patients with Parkinson disease on dopaminergic cells.

Authors:  W D Le; D B Rowe; J Jankovic; W Xie; S H Appel
Journal:  Arch Neurol       Date:  1999-02

8.  Mice deficient in TNF receptors are protected against dopaminergic neurotoxicity: implications for Parkinson's disease.

Authors:  Krishnan Sriram; Joanna M Matheson; Stanley A Benkovic; Diane B Miller; Michael I Luster; James P O'Callaghan
Journal:  FASEB J       Date:  2002-07-18       Impact factor: 5.191

9.  Isolation of highly infectious and pure adeno-associated virus type 2 vectors with a single-step gravity-flow column.

Authors:  A Auricchio; M Hildinger; E O'Connor; G P Gao; J M Wilson
Journal:  Hum Gene Ther       Date:  2001-01-01       Impact factor: 5.695

10.  Prostaglandin E2 receptor subtype 2 (EP2) regulates microglial activation and associated neurotoxicity induced by aggregated alpha-synuclein.

Authors:  Jinghua Jin; Feng-Shiun Shie; Jun Liu; Yan Wang; Jeanne Davis; Aimee M Schantz; Kathleen S Montine; Thomas J Montine; Jing Zhang
Journal:  J Neuroinflammation       Date:  2007-01-04       Impact factor: 8.322

View more
  141 in total

Review 1.  Misfolded α-synuclein and Toll-like receptors: therapeutic targets for Parkinson's disease.

Authors:  Dawn Béraud; Kathleen A Maguire-Zeiss
Journal:  Parkinsonism Relat Disord       Date:  2012-01       Impact factor: 4.891

2.  Regulatory T cells attenuate Th17 cell-mediated nigrostriatal dopaminergic neurodegeneration in a model of Parkinson's disease.

Authors:  Ashley D Reynolds; David K Stone; Jessica A L Hutter; Eric J Benner; R Lee Mosley; Howard E Gendelman
Journal:  J Immunol       Date:  2010-01-29       Impact factor: 5.422

3.  DNA methylation and methyl-binding proteins control differential gene expression in distinct cortical areas of macaque monkey.

Authors:  Katsusuke Hata; Hiroaki Mizukami; Osamu Sadakane; Akiya Watakabe; Masanari Ohtsuka; Masafumi Takaji; Masaharu Kinoshita; Tadashi Isa; Keiya Ozawa; Tetsuo Yamamori
Journal:  J Neurosci       Date:  2013-12-11       Impact factor: 6.167

4.  microRNA-155 Regulates Alpha-Synuclein-Induced Inflammatory Responses in Models of Parkinson Disease.

Authors:  Aaron D Thome; Ashley S Harms; Laura A Volpicelli-Daley; David G Standaert
Journal:  J Neurosci       Date:  2016-02-24       Impact factor: 6.167

Review 5.  Innate and adaptive immune responses in Parkinson's disease.

Authors:  Aubrey M Schonhoff; Gregory P Williams; Zachary D Wallen; David G Standaert; Ashley S Harms
Journal:  Prog Brain Res       Date:  2019-12-05       Impact factor: 2.453

6.  Nitrated {alpha}-synuclein-induced alterations in microglial immunity are regulated by CD4+ T cell subsets.

Authors:  Ashley D Reynolds; David K Stone; R Lee Mosley; Howard E Gendelman
Journal:  J Immunol       Date:  2009-04-01       Impact factor: 5.422

Review 7.  Parkinson's disease.

Authors:  Timothy R Mhyre; James T Boyd; Robert W Hamill; Kathleen A Maguire-Zeiss
Journal:  Subcell Biochem       Date:  2012

8.  Modeling Parkinson's disease pathology by combination of fibril seeds and α-synuclein overexpression in the rat brain.

Authors:  Poonam Thakur; Ludivine S Breger; Martin Lundblad; Oi Wan Wan; Bengt Mattsson; Kelvin C Luk; Virginia M Y Lee; John Q Trojanowski; Anders Björklund
Journal:  Proc Natl Acad Sci U S A       Date:  2017-09-12       Impact factor: 11.205

9.  Fcγ receptors are required for NF-κB signaling, microglial activation and dopaminergic neurodegeneration in an AAV-synuclein mouse model of Parkinson's disease.

Authors:  Shuwen Cao; Shaji Theodore; David G Standaert
Journal:  Mol Neurodegener       Date:  2010-10-26       Impact factor: 14.195

10.  Microglia acquire distinct activation profiles depending on the degree of alpha-synuclein neuropathology in a rAAV based model of Parkinson's disease.

Authors:  Vanesa Sanchez-Guajardo; Fabia Febbraro; Deniz Kirik; Marina Romero-Ramos
Journal:  PLoS One       Date:  2010-01-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.